Rodman & Renshaw reiterates their 'market outperform/speculative risk' rating and $12 price target on Spectrum Pharmaceuticals Inc (NASDAQ: SPPI), saying ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE